Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2011-03-15
2011-03-15
Ewoldt, G. R (Department: 1644)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
Reexamination Certificate
active
07906291
ABSTRACT:
Disclosed is a method for diagnosing multiple sclerosis and more particularly to a method for diagnosing multiple sclerosis by measuring levels of antibodies to glycans in a biological sample.
REFERENCES:
patent: 5030560 (1991-07-01), Sinor et al.
patent: 6972172 (2005-12-01), Dukler et al.
patent: 7537900 (2009-05-01), Dotan et al.
patent: 7572592 (2009-08-01), Dotan et al.
patent: 2004/0077023 (2004-04-01), Dotan et al.
patent: 2004/0241763 (2004-12-01), Dotan et al.
patent: 2006/0172338 (2006-08-01), Dotan et al.
patent: 2006/0234301 (2006-10-01), Dotan et al.
patent: WO 00/49412 (2000-08-01), None
patent: WO 01/14881 (2001-03-01), None
patent: WO 01/51207 (2001-07-01), None
patent: WO 02/18950 (2002-03-01), None
patent: WO 02/064556 (2002-08-01), None
patent: WO 03/000733 (2003-01-01), None
patent: WO 2004/015420 (2004-02-01), None
patent: WO-2004034031 (2004-04-01), None
BaoJ. Chromatogr. B., 699(1+2):463-480 (1997).
Berger et al.N. Engl. J. Med., 349:139-145 (2003).
Bozzaro et al.Cell Differentiation, 17:83-94 (1985).
Brex et al.N. Engl. J. Med., 346(3):158-164 (2002).
Carotenuto et al.J. Med. Chem., 44:2378-2381 (2001).
Comi et al.Lancet, 357:1576-1582 (2001).
Holme et al.Carbohydr. Res., 8:43-55 (1968).
Hou et al.J. Immunol., 170:4373-4379 (2003).
Jacobs et al.Ann. Neurol., 41(3):392-398 (1997).
Jacobs et al.N. Engl. J. Med., 343(13):898-904 (2000).
KurtzkeNeurol., 33(11):1444-1452 (1983).
Matsuda et al.Mol. Immun., 24(5):421-425 (1987).
McDonald et al.Ann. Neurol., 50(1):121-127 (2001).
O'Riordan et al.Brain, 121:495-503 (1998).
Papini et al.Proceedings of the 10thInternational Congress of Immunology, Monduzzi Editore, pp. 1239-1244 (1998).
Poser et al.Ann. Neurol., 13(3):227-231 (1983).
Rongen et al.J. Immunol. Meth., 204(2):105-133 (1997).
Saveliev et al.Immun. Letters, 86:291-297 (2003).
Schmalzing et al.Electrophoresis, 18(12-13):2184-2193 (1997).
Schwarz et al.Glycobiol., 13(11):749-754 (2003).
Self et al.Curr. Opin. Biotechnol., 7:60-65 (1996).
Weinshenker et al.Brain, 112(part VI):1419-1428 (1989).
Zhan et al.Biochem. Biophys. Res. Commun., 308(1):12-22 (2003).
Mazzucco, S., et al. Bioorg. Med. Chem. Letters (1999) 9:167-172.
Schwarz, M., et al., J. Neuro. Sci. (2006) 244:59-68.
Alberts et al., “Sugars Are Food Molecules of the Cell”, inMolecular Biology of the Cell, Garland Publishing Inc., New York & London, pp. 50-51 (1983).
Stryer, L.,Biochemistry, 4thEdition, W.H. Freeman and Company, New York, NY, pp. 472-473 (1995).
Banin et al., “A Novel Linear Code® Nomenclature for Complex Carbohydrates”,Trends Glycoscience Glycotech., 14(77):127-137 (2002).
Bergamaschi, R., “Prognostic Factors in Multiples Sclerosis”,Int. Rev. Neurobiol., 79:423-447 (2007).
Binder et al., “The role of natural antibodies in atherogenesis”,J. Lipid Res., 46:1353-1363 (2005).
Boneschi et al., “Mitoxantrone for multiple sclerosis (Review)”,Cochrane Database of Systematic Rev., John Wiley & Sons, 4:CD002127 (2005).
Brusaferri et al., “Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials”,J. Neurol., 247(6):435-442 (2000).
Confavreux et al., “Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process”,Brain, 126:770-782 (2003).
Dalton et al., “Application of the new McDonald Criteria to Patients with Clinically Isolated Syndromes Suggestive of Multiple Sclerosis”,Ann. Neurol., 52:47-53 (2002).
Dotan et al., “Anti-glycan antibodies as biomarkers for diagnosis and prognosis”,Lupus, 15(7):442-450 (2006).
Dovio et al., “Immediate Fall of Bone Formation and Transient Increase of Bone Resorption in the Course of High-Dose, Short-Term Glucocorticoid Therapy in Young Patients with Multiple Sclerosis”,J. Clin. Endocrinol. Metab., 89(10):4923-4928 (2004).
Durelli et al., “MRI activity and neutralising antibody as predictors of response to interferon β treatment in multiple sclerosis”,J. Neurol. Neurosurg. Psychiatry, 79:646-651 (2008).
Felici et al., “Phage-Displayed Peptides as Tools for Characterization of Human Sera”,Meth. Enzymol., 267:116-129 (1996).
Fisniku et al., “Disability and T2MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis”,Brain, 131:808-817 (2008).
Freedman et al., “Anti-α-glucose-based glycan IgM antibodies predict relapse activity in multiple sclerosis after the first neurological event”,Multiple Sclerosis, 15(4):422-430 (2009).
Freedman et al., “Recommended Standard of Cerebrospinal Fluid Analysis in the Diagnosis of Multiple Sclerosis”,Arch. Neurol., 62:865-870 (2005).
Gonsette, R.E., “Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis”,Exp. Opin. Pharmacother., 8(8):1103-1116 (2007).
Gyorgy et al., “Natural autoantibodies reactive with glycosaminoglycans in rheumatoid arthritis”,Arthritis Res. Ther., 10(5):1-12 (2008).
Johnson, K.P., “Control of multiple sclerosis relapses with immunomodulating agents”,J. Neurol. Sci., 256:(1):S23-S28 (2007).
Kappos et al., “Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study”,Lancet, 370(9585):389-397 (2007).
Kuhle et al., “Lack of Association between Antimyelin Antibodies and Progression to Multiple Sclerosis”,N. Engl. J. Med., 356(4):371-378 (2007).
Leary et al., “Primary Progressive Multiple Sclerosis Current and Future Treatment Options”,CNS Drugs, 19(5):369-376 (2005).
Lolli et al., “An N-glucosylated peptide detecting disease-specific autoantibodies, biomarkers of multiple sclerosis”,Proc. Natl. Acad. Sci. U.S.A., 102(29):10273-10278 (2005).
Lolli et al., “The glycopeptides CSF114(Glc) detects serum antibodies in multiple sclerosis”,J. Neuroimmunol., 167:131-137 (2005).
Mandrioli et al., “A multifactorial prognostic index in multiple sclerosis. Cerebrospinal fluid IgM oligoclonal bands and clinical features to predict the evolution of the disease”,J. Neurol., 255:1023-1031 (2008).
Miller et al., “Differential diagnosis of suspected multiple sclerosis: a consensus approach”,Multiple Sclerosis, 14:1157-1174 (2008).
Miller, D. H., “Biomarkers and Surrogate Outcomes in Neurodegenerative Disease: Lessons from Multiple Sclerosis”,NeuroRx, 1:284-294 (2004).
Munari et al., “Therapy with glatiramer acetate for multiple sclerosis (Review)”,Cochrane Database of Systematic Rev., John Wiley & Sons, 4:CD004678 (2003).
Murray, T.J., “The cardiac effects of mitoxantrone: do the benefits in multiple sclerosis outweigh the risks?”,Exp. Opin. Drug Safety, 5(2):265-274 (2006).
Perrin et al., “A National Survey of Physician Perspectives of the Unmet Needs in the Treatment of Multiple Sclerosis”,JMCP, 15(7):572-573 (2009) (Abstract Only).
Pirko et al., “A human antibody that promotes remyelination enters the CNS and decreases lesion load as detected by T2-weighted spinal cord MRI in a virus-induced murine model of MS”,FASEB J., 18:1577-1579 (2004).
Pittock et al., “Clinical Implications of Benign Multiple Sclerosis: A 20-Year Population-Based Follow-up Study”,Ann. Neurol., 56:303-306 (2004).
Polman et al., “Diagnostic Criteria for Multiple Sclerosis: 2005 Revisions to the ‘McDonald Criteria’”,Ann. Neurol., 58:840-846 (2005).
Rice et al., “Interferon in relapsing-remitting multiple sclerosis (Review)”,Cochrane Database of Systematic Rev., John Wiley & Sons, 4:CD002002 (2001).
Rio et al., “Relationship between MRI lesion activity and response to IFN-β in relapsing-remitting multiple sclerosis patients”,Mult.
Dotan Nir
Dukler Avinoam
Ewoldt G. R
Glycominds Ltd.
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
LandOfFree
Method for diagnosing multiple sclerosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for diagnosing multiple sclerosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for diagnosing multiple sclerosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2645945